FDA Inspection 1236571 — Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc. — FEI 3022318150

The FDA completed an inspection of Intercept Pharmaceuticals, Inc. on Apr 22, 2024 in Morristown, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Apr 22, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Morristown, NJ (United States)

Additional Details

Sponsor, Contract Research Organization

Citations

IDCFRDescription
748221 CFR 312.50General responsibilities of sponsors